Development of a visualization tool to estimate out-of-pocket costs for systemic cancer therapy in Japan and claims-based agreement evaluation: the VEST-Ca study [0.03%]
日本自助付费癌症治疗费用估算的可视化工具开发及基于保险理赔资料的一致性评估:VEST-Ca研究
Kazunori Honda,Kazuhiro Shimomura,Hiroya Taniguchi et al.
Kazunori Honda et al.
Background: Financial toxicity is increasingly recognized as a major barrier to high-quality cancer care. However, regimen-specific estimates of out-of-pocket (OOP) costs are rarely available at treatment planning. We dev...
Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study) [0.03%]
老年可切除胰腺癌新辅助化疗吉西他滨联合白蛋白结合型紫杉醇与吉西他滨联合S-1的III期随机对照研究(JCOG2101C PRESTIGE研究)
Yusuke Sano,Masato Ozaka,Shuichi Aoki et al.
Yusuke Sano et al.
Neoadjuvant gemcitabine plus S-1 (GS) followed by surgery and adjuvant S-1 is the standard of care for resectable pancreatic cancer. Since ~73% of newly diagnosed pancreatic cancer patients are aged ≥70, effective treatments are strongly n...
Non-surgical definitive treatment and geriatric assessment in older patients with locally advanced head and neck cancer [0.03%]
老年局部晚期头颈部鳞癌患者非手术根治性治疗的术前综合评估专家共识
Koichi Yasuda,Yoshitaka Honma,Yuri Ueda et al.
Koichi Yasuda et al.
Population aging is rapidly progressing worldwide, and Japan has the most advanced aging population. Consistent with this trend, the proportion of older patients with head and neck cancer has markedly increased. Non-surgical definitive trea...
Age-standardized mortality-to-incidence ratio for non-melanoma skin cancer in the world [0.03%]
全球非黑色素皮肤癌死亡率-发病率比的标准化值
Hadrien Charvat,Kumiko Saika
Hadrien Charvat
Contrasting responses to neoadjuvant immunotherapy in synchronous transverse colon cancers with discordant mismatch repair status [0.03%]
错配修复状态不一致的同步横结肠癌对新辅助免疫治疗的不同反应
Koki Omoto,Fuminori Teraishi,Naoki Onoda et al.
Koki Omoto et al.
Mismatch repair (MMR) status is a critical predictive biomarker for immune checkpoint inhibitor (ICI) efficacy in colorectal cancer (CRC); however, direct in vivo comparisons of ICI responsiveness between MMR-deficient (dMMR) and MMR-profic...
Resolution of peritoneal metastases in CLDN18.2-positive gastric cancer treated with CAPOX plus zolbetuximab [0.03%]
CAPOX联合佐妥昔单抗治疗CLDN18.2阳性胃癌腹膜转移患者获得缓解
Hironori Midorikawa,Nobukazu Hokamura,Taketoshi Fukasawa et al.
Hironori Midorikawa et al.
Author's reply to 'Trends in Usage and Drug Costs of Immune-Checkpoint Inhibitors in Japan' [0.03%]
作者对“日本免疫检查点抑制剂使用趋势及药物成本”的回应答复
Akina Takami,Koki Yamashita,Ataru Igarashi
Akina Takami
Sacituzumab govitecan in Japanese participants with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study [0.03%]
Sacituzumab govitecan治疗HR+/HER2-转移性乳腺癌的日本患者:II期ASCENT-J02研究的主要结果
Akihiko Shimomura,Takahiro Kogawa,Koji Matsumoto et al.
Akihiko Shimomura et al.
Background: Sacituzumab govitecan (SG), a Trop-2-directed antibody-drug conjugate, is approved outside Japan for previously treated hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) u...
Postoperative skeletal muscle loss is associated with high fat mass in patients undergoing Esophagectomy for esophageal cancer [0.03%]
食管癌行食管切除术患者的术后骨骼肌减少与高脂肪量有关
Shota Sawai,Shinsuke Sato,Eiji Nakatani et al.
Shota Sawai et al.
Objective: Esophageal cancer is one of the most lethal cancers worldwide. Loss of skeletal muscle after esophagectomy worsens prognosis; however, it remains unclear which musculoskeletal factors, such as muscle and fat ma...